# GH Research PLC > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/GH Research PLC). ## Overview GH Research PLC is a clinical-stage biopharmaceutical company focused on developing mebufotenin-based therapies for treatment-resistant depression. The company is organized through its Irish holding company and wholly owned Irish subsidiary, with its pipeline centered on GH001, an inhalable product candidate, and GH002, an intravenous product candidate. ## Products & services • GH001 inhalable mebufotenin for treatment-resistant depression • GH002 intravenous mebufotenin for treatment-resistant depression • Clinical development and trial execution for psychiatric therapeutics • Drug candidate advancement from preclinical through pivotal-stage studies - **GH001** (50%) — Inhalable mebufotenin product candidate being developed for TRD. - **GH002** (30%) — Intravenous mebufotenin product candidate being developed for TRD. - **Clinical development services** (20%) — Internal research, clinical operations, and regulatory development work. - GH001 inhalable mebufotenin for treatment-resistant depression - GH002 intravenous mebufotenin for treatment-resistant depression - Clinical development and trial execution for psychiatric therapeutics - Drug candidate advancement from preclinical through pivotal-stage studies ## Customers GH Research does not sell commercial drugs today; its direct economic stakeholders are patients, physicians, clinical investigators, regulators, and prospective commercialization partners. The intended end users are adults with treatment-resistant depression, while the immediate buyers in any future commercial model would likely be hospitals, clinics, payers, and specialty prescribers. Current activity is centered on clinical trial participants and the medical centers that conduct and support studies. - **Patients with treatment-resistant depression** (primary) — The core therapeutic population targeted by GH001 and GH002 for eventual treatment use. - **Psychiatrists and specialty clinics** (primary) — Physicians and treatment centers that would administer or prescribe the therapy if approved. - **Clinical trial sites** (primary) — Hospitals, research centers, and investigators that enroll patients and generate clinical data. - **Regulators and ethics committees** (secondary) — They review safety, efficacy, and trial design before later-stage development and approval. - **Future commercial payers** (emerging) — Insurers and health systems that would influence access and reimbursement after approval. - Patients with treatment-resistant depression targeted by the pipeline - Psychiatrists and specialty prescribers who would adopt the therapy - Clinical trial sites and investigators running GH001/GH002 studies - Regulators reviewing clinical and safety data for approval - Potential future payers and healthcare systems purchasing treatment ## Geography The company is incorporated in Ireland and has its registered office in Dublin, while its securities are listed in the United States on Nasdaq. Its current development work is international in nature because clinical biopharmaceutical programs typically require trial sites, regulators, and service providers across multiple jurisdictions. The available reports do not disclose country-by-country revenue, consistent with a pre-commercial development stage. - Incorporated in Ireland with headquarters functions in Dublin - Listed on Nasdaq in the United States - Development activities are international rather than tied to one market - No country-level revenue disclosure is provided in the excerpts - Clinical and regulatory exposure spans multiple jurisdictions ## Strategy GH Research’s strategy is to advance mebufotenin-based therapies through clinical development, with GH001 as the central program and GH002 as a follow-on candidate. The company’s direction depends on generating clinical evidence, aligning trial design with regulators, and preserving capital to fund development through key milestones. - **Advance GH001 clinical program** (short-term) — GH001 is the lead asset and the main path to proof of concept and eventual approval. - **Develop GH002** (medium-term) — A second product candidate broadens the platform and provides an additional development path. - **Maintain development funding** (short-term) — Clinical programs require sustained capital to support trials, regulatory work, and operations. - Advance GH001 through late-stage clinical development - Develop GH002 as a second mebufotenin formulation - Build regulatory alignment around pivotal trial design - Use financing to extend runway for development milestones ## Risks The main risks are clinical and regulatory: the company may fail to demonstrate efficacy and safety, may not secure favorable FDA alignment, or may face trial delays and clinical hold risk. As a clinical-stage biopharmaceutical company, GH Research also depends on external financing and is exposed to valuation, dilution, and execution risk before any commercial revenue exists. - **Clinical development failure** [critical] — Drug candidates may not demonstrate acceptable efficacy, safety, or tolerability in trials. - **Regulatory misalignment** [high] — The company needs regulatory agreement on pivotal design and development plans. - **Clinical hold risk** [high] — Future trials can be delayed or halted by regulators if safety or protocol issues arise. - **Financing and dilution** [high] — As a pre-revenue biotech, the company relies on equity capital to fund operations. - Clinical trials may fail to show sufficient efficacy or safety - FDA may not align on pivotal program design or timelines - Future studies may be placed on clinical hold - The company depends on external financing and share issuance - Development timelines can slip due to regulatory or operational delays ## Accounting As a clinical-stage biotech, GH Research’s reported results are shaped by fair value measurements of marketable securities, share-based compensation, lease accounting, and the timing of trial-related expenses. Because the business has no commercial product revenue in the excerpts, investors should focus on how capital raises, cash usage, and estimate-driven balances affect the financial statements and liquidity disclosures. - **Fair value of marketable securities** — Changes can affect cash-like resources and reported results. - **Share-based compensation** — Raises operating expense without cash outflow. - **Lease accounting** — Important for understanding operating versus financing cash usage. - **Clinical trial expense timing** — Can cause volatility in research and development expense. - Fair value of marketable securities affects reported liquidity - Share-based payments can materially affect operating expense - Lease liability accounting impacts financing cash flows - Clinical development costs are expensed as incurred - Going concern and runway disclosures depend on cash estimates --- *Last updated: 2026-09-28T12:03:43.276847+00:00*